Similar articles for PMID: 21738752

Year	Number of Results
2000	1
2001	3
2002	1
2003	1
2004	1
2005	3
2006	3
2008	8
2009	18
2010	11
2011	11
2012	7
2013	3
2014	8
2015	8
2016	6
2017	3
2018	1
2019	3
2020	4
2022	1
2024	0

1

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.

Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, Aboulker JP, Taburet AM, Molina JM, Massip P, Marchou B, Izopet J; ANRS 106-Window Study Team. Delobel P, et al. PLoS One. 2011;6(6):e21655. doi: 10.1371/journal.pone.0021655. Epub 2011 Jun 27. PLoS One. 2011. PMID: 21738752 Free PMC article. Clinical Trial.

2

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, Hammer SM, Palmer S, Vaida F, Coffin JM, Mellors JW. Halvas EK, et al. J Infect Dis. 2010 Mar;201(5):672-80. doi: 10.1086/650542. J Infect Dis. 2010. PMID: 20102272 Free PMC article.

3

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.

Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K. Bacheler LT, et al. Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84. doi: 10.1128/AAC.44.9.2475-2484.2000. Antimicrob Agents Chemother. 2000. PMID: 10952598 Free PMC article.

4

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Paredes R, et al. J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543. J Infect Dis. 2010. PMID: 20102271 Free PMC article.

5

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA. Geretti AM, et al. J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8. J Acquir Immune Defic Syndr. 2009. PMID: 19779307

6

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group. Ngo-Giang-Huong N, et al. PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23. PLoS One. 2011. PMID: 22132100 Free PMC article.

7

Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Koval CE, Dykes C, Wang J, Demeter LM. Koval CE, et al. Virology. 2006 Sep 15;353(1):184-92. doi: 10.1016/j.virol.2006.05.021. Epub 2006 Jun 21. Virology. 2006. PMID: 16797050 Free PMC article.

8

Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.

Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, Hance AJ. Lecossier D, et al. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):37-42. doi: 10.1097/00126334-200501010-00007. J Acquir Immune Defic Syndr. 2005. PMID: 15608522 Clinical Trial.

9

Distinct drug resistance profile of HIV-1 subtype A strain circulating in Georgia.

Dvali N, Chkhartishvili N, Karchava M, Sharvadze L, Tsertsvadze T. Dvali N, et al. Georgian Med News. 2015 Mar;(240):19-24. Georgian Med News. 2015. PMID: 25879553

10

Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.

Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, Orrell C, Zeinecker J, Sanne I, Wood R, McIntyre J, Stevens W; CIPRA-SA project 1 study team. Wallis CL, et al. Antivir Ther. 2012;17(2):313-20. doi: 10.3851/IMP1985. Epub 2011 Nov 18. Antivir Ther. 2012. PMID: 22293461 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

91 results

Results by year